Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of this study is to determine the maximum tolerated dose (MTD) of Oratecan in combination with capecitabine

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hanmi Pharmaceutical Company Limited
• Treatments: Camptothecin; Capecitabine; Irinotecan

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed advanced solid tumor

• Patients who have experienced progressive disease despite of conventional anticancer therapy. Patients who cannot expect effective treatment or prolonged survival with conventional anticancer therapy

• Previous chemotherapy, radiotherapy and surgical operation are allowed if they are discontinued for at least 4 weeks prior to D0 and all adverse events are resolved

• Aged ≥19

• Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2

• A life expectancy greater than 12 weeks

• Adequate bone marrow, renal and liver function.

• Subjects must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow up assessments and procedures

Exclusion Criteria:

• Patients with hematopoietic malignancies,uncontrolled infection, CNS metastasis.

• Patients who have undergone hematopoietic stem cell transplantation (HSCT) or are candidates for planned HSCT

• Patients who have GI malabsorption or difficulty taking oral medication

• Patients who have psychiatric or congenital disorder Subjects who, in the investigator's opinion, cannot be treated per protocol due to functional impairments

• Pregnant or breast-feeding patients; Women of childbearing potential without adequate contraception (Men must use adequate contraception.)